The National Pharmaceutical Pricing Authority (NPPA) recently announced a directive to lower the maximum retail price (MRP) of three essential anti-cancer drugs in an effort to enhance patient access and affordability. What are the names of these three anti-cancer drugs?
1
Trastuzumab, Osimertinib, and Durvalumab
2
Trastuzumab, Imatinib, and Durvalumab
3
Osimertinib, Nivolumab, and Pembrolizumab
4
Trastuzumab, Osimertinib, and Bevacizumab